Clinical activity of celecoxib in metastatic malignant melanoma

Cancer Investigation

Volumn 24, Issue 8, 2006, Pages 740-746

  Wilson, Kenneth S ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

Celecoxib; Cyclo oxygenase; Inhibition; Melanoma

Indexed keywords

CANCER VACCINE; CELECOXIB; ROFECOXIB;

ADULT; AGED; AMELANOTIC MELANOMA; ARTICLE; BRAIN METASTASIS; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; CLINICAL ARTICLE; CONSERVATIVE TREATMENT; DRUG ACTIVITY; DRUG CHOICE; DRUG EFFECT; DRUG WITHDRAWAL; DYSPHASIA; FEMALE; FOLLOW UP; GASTROINTESTINAL SYMPTOM; HUMAN; KIDNEY METASTASIS; LUNG METASTASIS; MALE; MELANOMA; METASTASIS; PRIORITY JOURNAL; SURVIVAL TIME; THORAX RADIOGRAPHY; TRANSIENT ISCHEMIC ATTACK; TREATMENT OUTCOME; TREATMENT RESPONSE; TUMOR REGRESSION; WEAKNESS;

ADULT; AGED; AGED, 80 AND OVER; CYCLOOXYGENASE 2 INHIBITORS; FEMALE; HUMANS; MALE; MELANOMA; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PYRAZOLES; RADIOGRAPHY, ABDOMINAL; RADIOGRAPHY, THORACIC; SKIN NEOPLASMS; SULFONAMIDES; TREATMENT OUTCOME;

EID: 33845658081     PISSN: 07357907     EISSN: 15324192     Source Type: Journal    
DOI: 10.1080/07357900601063790     Document Type: Article

References (29)

1. Brand, C.U.; Ellwanger, U.; Stroebel, W.; et al. Prolonged survival of 2 years or longer for patients with disseminated melanoma. an analysis of related prognostic factors. Cancer 1997, 79(12), 2345-2353.
2. Rosenberg, S.A.; Yang, J.C.; Topalian, S.L. et al. Treatment of 283 consecutive patients with metastatic melanoma or renal cell cancer using high-dose bolus interleukin 2. J Am. Med. Assoc. 1994, 271(12), 907-913.
3. Legha, S.S.; Ring, S.; Eton, O.; et al. Development of a biochemotherapy regimen with concurrent administration of cisplatin, vinblastine, dacarbazine, interferon alfa, and interleukin-2 for patients with metastatic melanoma. J. Clin. Oncol. 1998, 16(5), 1752-1759.
4. National Comprehensive Cancer Network. Clinical practice guidelines in Oncology v.1.2005: Melanoma. Houghton AN (Chairperson). http://www.nccn.org/ professionals/physician_gls/f_guidelines.asp?button=I+Agree#site.
5. Denkert, C.; Kobel, M.; Berger, S.; et al. Expression of cyclooxygenase 2 in human malignant melanoma. Cancer Res 2001, 61(1), 303-308.
6. Reich, R.; Royce, L.; Martin, G.R.; Eicosapentaenoic acid reduces the invasive and metastatic activities of malignant tumor cells. Biochem Biophys Res Commun. 1989, 160(2), 559-564.
7. Goulet, A.C.; Einsphar, J.G.; Alberts, D.S.; et al. Analysis of COX-2 expression during malignant melanoma progression. Cancer Biology & Therapy. 2003: 2(6), 713-718.
8. Vogt, T.; McClelland, M.; Jung, B.; et al. Progression and NSAID-induced apoptosis in malignant melanomas are independent of cyclo-oxygenase II. Melanoma Research. 2001, 11(6), 587-599.
9. Wilson, K.S. Unexpected benefit of celecoxib therapy in acute gout. http://bmj.com/cgi/eletters/325/7371/980#26644 Vol 325, November 2002.
10. Health Canada. Health Canada Endorsed Important Safety Information on Celebrex (celecoxib) capsules, a selective cyclooxygenase-2 (COX-2) inhibitor. Therapeutic Products Directorate, Dec 22, 2004. http://www.hc-sc.gc.ca/hpfb- dgpsa/tpddpt/celebrex2_hpc_e.html.
11. Balch, C.M.; Buzaid, A.C.; Soong, S.-J.; et al. Final Version of the American Joint Committee on Cancer Staging System for Cutaneous Melanoma. J. Clin. Oncol. 2001, 19, 16, 3635-3648.
12. Therasse, P.; Arbuck, S.G.; Eisenhauer, E.A.; et al. New guidelines to evaluate the response to treatment in solid tumors. J. Natl. Cancer Inst. 2000, 92, 205-216.
13. Millward, M.J.; Bedikian, A.Y.; Conry, R.M.; et al. Randomized multinational phase 3 trial of dacarbazine (DTIC) with or without Bcl-2 antisense (oblimersen sodium) in patients (pts) with advanced malignant melanoma (MM): Analysis of long-term survival. Proc Am Soc Clin Oncol 2004, abstract 7505.
14. Middleton, M.R.; Grob, J.J.; Aaronson, N.; et al. Randomized Phase III Study of Temozolomide Versus Dacarbazine in the Treatment of Patients With Advanced Metastatic Malignant Melanoma. J Clin Oncol 2000, 18(1), 158-166.
15. Xu, X.C. COX-2 inhibitors in cancer treatment and prevention, a recent development. Anticancer Drugs. 2002, 13 (2), 127-137.
16. Tsuji, S.; Tsujii, M.; Kawano, S.; Hori, M. Cyclooxygenase-2 upregulation as a perigenetic change in carcinogenesis. J. Exp. Clin. Cancer Res. 2001, 20, 117-129
17. Caivano, M.; Cohen, P. Role of mitogen-activated protein kinase cascades in mediating lipopolysaccharide-stimulated induction of cyclooxygenase-2 and IL-1 beta in RAW264 macrophages. J. Immunol. 2000, 164, 3018-3025.
18. Kirtikara, K.; Raghow, R.; Laulederkind, S.J.; et al. Transcriptional regulation of cyclooxygenase-2 in the human microvascular endothelial cell line, HMEC-1: control by the combinatorial actions of AP2, NF-IL-6 and CRE elements. Mol. Cell. Biochem. 2000, 203, 41-51.
19. Torisu, H.; Ono, M.; Kiryu, H.; et al. Macrophage infiltration correlates with tumor stage and angiogenesis in human malignant melanoma: possible involvement of TNF-alpha and IL-1-alpha. Int. J. Cancer 2000, 85, 182-188.
20. Voronov, E.; Shouval, D.S.; Krelin, Y.; et al. IL-1 is required for tumor invasiveness and angiogenesis. Proc. Natl. Acad. Sci. USA 2003, 100, 2645-2650.
21. Bedikian, A.Y.; Legha, S.S.; Mavligit, G.; et al. Treatment of uveal melanoma metastatic to the liver: a review of the M. D. Anderson Cancer Center experience and prognostic factors. Cancer. 1995, 76(9), 1665-1670.
22. Figueiredo, A.; Caissie, A.L.; Callejo, S.A.; et al. Cyclooxygenase-2 expression in uveal melanoma: novel classification of mixed-cell-type tumours. Can. J. Ophthalm. 2003, 38(5), 352-356
23. Mertens, W.C.; Lohmann, R.C. Oral indomethacin and ranitidine in advanced melanoma: a phase 2 study. Clin. Oncol. 1996, 8(2), 112-115.
24. Miller, R.L.; Steis, R.G.; Clark, J.W.; et al. Randomized trial of recombinant alpha-2b interferon with or without indomethacin in patients with metastatic malignant melanoma. Cancer Res. 1989, 49(7), 1871-1876.
25. Song, X.; Lin, H.-P.; Johnson, A.J.; et al. Cyclooxygenase-2, player or spectator in cyclooxygenase-2 inhibitor-induced apoptosis in prostate cancer cells. J. Nat. Cancer Inst. 2002, 94, 8, 585-591.
26. Vogt, T.; McClelland, M.; Jung, B.; et al. Progression and NSAID-induced apoptosis in malignant melanomas are independent of cyclo-oxygenase II. Melanoma Research 2001, 11(6), 587-599.
27. NCCR Molecular Oncology. 2004. Pfizer extends its collaboration with the CePO and NCCR Molecular Oncology. Available online at: http://www.nccr-oncology. ch/en/presscorner/comm_pfizer.htm.
28. Beth Israel Deaconess Medical Centre. Phase II pilot trial of low dose, continuous infusion paclitaxel and oral celecoxib in patients with advanced melanoma, 2005. Available online at: http://bidmc.harvard.edu/display.asp? node_id=497.
29. Gogas, H.; Polyzos, A.; Tsoutsos, D.; et al. Temozolomide in combination with celecoxib in patients with advanced melanoma. a Phase II study of the Hellenic Cooperative Oncology Group. Proc. Am. Soc. Clin. Oncol. 2005, abstract 7554.